All times shown in GMT - please see the Full Event Guide for CET

8:30 am Virtual Coffee & Registration

9:00 am Chair’s Opening Remarks

9:15 am Industry Leader’s Fireside Chat

10:00 am Providing an Overview of the European CAR-T Landscape

10:30 am Morning Refreshments & Speed Networking

Research & Development

Translation

Manufacturing & Commercialisation

Breakthroughs in Solid Tumours: Expanding CAR-TCR Indications

Characterising Cell Types to Select for Highly Efficacious, Cost-Effective Products

Improving Access to CAR-TCR Across Europe

11.30 Equipping T Cells for Trafficking,
Persistence and Maximum Efficacy in the Solid Tumour Setting

To see full session details, download the full event guide

Dolores Schendel, CEO & CSO, Medigene AG

 

11.30 Providing Mechanistic Rationale
for Combination Therapies Through Functional Characterisation

To see full session details, download the full event guide

Marc Van Dijk, CTO, Agenus

 

11.30 Implications of Varied Regulatory
Standards and Hospital Exemption Rules on Drug Product Safety and Commercial Ability

To see full session details, download the full event guide

Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine

12:00 Enhancing the Safety and Efficacy of CAR-T via Regulation of CAR Expression

To see full session details, download the full event guide

Yoav Ben Yaacov, Co-Founder & CEO, CTG-Pharma

 

12:00 Improving In Vivo Efficacy by Selecting for Favourable Functional, Phenotypic and Metabolic Profiles

To see full session details, download the full event guide

Rogier Reijmers, Principal Scientist, Lumicks

 

12.00 Discussing the Implications of Brexit for Cell and Gene Therapies

To see full session details, download the full event guide

John Johnston, Clinical Assessor, MHRA

 

12.30 One Stone, Three Birds: Tri-Functional CAR-T for Solid Tumours

To see full session details, download the full event guide

Bin Gao, CSO & CEO, Timmune Biotech

 

12.30 Discussing ‘Gold Standards’ and Innovations in Assay Development

To see full session details, download the full event guide

Eric Alonzo, Associate Director, Analytical Development, bluebird bio

12.30 Can we afford a Cure ? - Payer’s
Perspectives on Value Based Agreements & Innovative Contracting to Reimburse Cell & Gene Therapies

To see full session details, download the full event guide

Omar Ali, Visiting Lecturer, Value Based Pricing & Former Adviser to NICE, University of Portsmouth

 

1:00 pm Lunch & Networking

Research & Development

Translation

Manufacturing & Commercialisation

Next-Generation Gene Engineering
& Non-Viral Delivery

Clinical Development for Allogeneic Therapies

Pricing & Reimbursement Strategy in a Single-Payer System

14.00 Developing a qCART Platform to Produce Virus-Free Optimal CAR-T Systems

To see full session details, download the full event guide

Sareina Wu, Founder & CSO, Genome Frontier Therapeutics

 

14.00 Identifying the Best Allogeneic Cell and Donor Populations

To see full session details, download the full event guide

Michael Koslowski, CEO, GammaDelta Therapeutics

 

14.00 Case Study: Challenges and Potential Solutions to Value Assessment and Reimbursement of CAR-T Therapies in Europe

To see full session details, download the full event guide

Trevor Bacon, Compound Market Access Leader (EMEA), Cell & Gene Therapies, Janssen

 

14:30 Sharing Innovations in Non-Viral Vector Engineering

To see full session details, download the full event guide

Holger Hoff, Head of MDCell, Helmholtz Innovation Lab, Max-Delbrück-Center for Molecular Medicine

 

14:30 Exploiting a Single Receptor for Solid Tumour and Haematological Conditions in Autologous and Allogeneic Settings

To see full session details, download the full event guide

David Gilham, CSO, Celyad Oncology

 

14:30 Bridging the Gap Between “Evidence” and “Value” for Cell and Gene Therapies

To see full session details, download the full event guide

Jie Zhang, Head of Global Access & Value, Cell & Gene Therapy, Novartis

 

15:00 Generating CAR T Cells in Vivo

To see full session details, download the full event guide

Christian Buchholz, Group Leader, Paul-Ehrlich-Institut

 

15:00 Clinical Development of the Allogeneic PBCAR-T Cells Demonstrating Persistence and Investigating its Correlation with Efficacy

To see full session details, download the full event guide

Christopher Heery, CMO, Precision Biosciences

 

15:00 Describing Innovative Payment Models for Reimbursement of High-Cost, Single-Treatment Therapies to Improve Patient Access

To see full session details, download the full event guide

Alla Uhrlandt, EMEA Strategic Pricing Manager Cell & Gene Therapies, Janssen

 

3:30 pm Afternoon Refreshments & Tech Slam

Research & Development

Manufacturing
Track

Development & Commercialisation Track

Optimising CAR-TCR Design for Improved Efficacy, Safety & Persistence

Clinical Outcomes & Toxicity Management to Minimise Additional Treatment

Advancing Manufacturing & Automation for High Quality Cell Therapy Products at Scale

16:00 The Affinity-Avidity Conundrum: Optimising Receptor-Target Interactions for Improved Safety and Efficacy

To see full session details, download the full event guide

Leah Sibener, Co-Founder & Head of Therapeutic Discovery, 3T Biosciences

 

16:30 Defining Therapeutic Endpoints for Rapid Assessment of Clinical Benefit

To see full session details, download the full event guide

Amit Patel, Consultant, Cellular Therapies and Stem Cell Transplantation, The Christie NHS

 

16:00 Developing Closed-System Clinical Scale Production Method for Reduced Cost of Manufacture

To see full session details, download the full event guide

Volker Huppert, CDO, Glycostem

 

16:30 Engineering Strategies for Fitness in the Solid Tumour Microenvironment

To see full session details, download the full event guide

Francesco Marincola, CSO, Refuge Biotech

 

16:30 Sharing Experience of Clinical
Development of CAR-T in Liquid and Solid Tumour Indications

To see full session details, download the full event guide

Hong Ma, SVP, Clinical Development, CARsgen Therapeutics

 

16.30 Developing CD8-Independent, Next-Generation TCRs for Solid Tumour Indications

To see full session details, download the full event guide

Ali Mohamed, VP, CMC, Immatics Biotechnologies

17:00 Optimising T Cell Metabolism to Enhance Persistence in Solid Tumours

To see full session details, download the full event guide

Ramon Klein Geltink, Investigator, British Columbia Children’s Hospital

 

17:00 Discussing Success in Pre-Conditioning and Toxicity Management for Safe and Effective Therapeutic Delivery

To see full session details, download the full event guide

Adrian Bot, VP, Translational Medicine, Kite: A Gilead Company

 

17.00 Discussing Innovations in CAR-T
Manufacturing Platforms through Iterative Analysis and Improvement

To see full session details, download the full event guide

Steven Feldman, Director Manufacturing & Process Development, Stanford School of Medicine

 

5:30 pm Chair’s Closing Remarks

6:45 pm End of Day 1